JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

Bibliography

• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2(6):473-88
   PubMed Web of Science ®Google Scholar
• Klarescog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-72
   PubMed Web of Science ®Google Scholar
• Curtis J, Patkar N, Xie A, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthritis Rheum 2007;56(4):1125-33
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Why does rheumatoid arthritis involve the joints? N Engl J Med 2007;356(23):2419-20
   PubMed Web of Science ®Google Scholar
• Lipsky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 16th edition. McGraw-Hill; New York: 2005. p. 1968-77
   Google Scholar
• Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33(3):305-15
   PubMed Web of Science ®Google Scholar
• Maini RN, Feldmann M. Cytokine therapy in rheumatoid arthritis. Lancet 1996;348(9030):824-5
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xi J, Patkar N, Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56(12):4226-7
   PubMed Web of Science ®Google Scholar
• Hetland ML, Christensen IJ, Tarp U, Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22-32
   PubMed Web of Science ®Google Scholar
• Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72(6):1037-47
   PubMed Web of Science ®Google Scholar
• Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial. J Rheumatol 2011;38(12):2548-56
   PubMed Web of Science ®Google Scholar
• Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4(Suppl 3):S233-42
   PubMedGoogle Scholar
• Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8(7):538-42
   PubMed Web of Science ®Google Scholar
• Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010;6(2):189-95
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week muticentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994;12(3):262-77
   PubMed Web of Science ®Google Scholar
• Ihle JN, Witthuhn BA, Quelle FW, Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994;19(5):222-7
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Janus kinase family and signaling through members of the cytokine receptor superfamily. Proc Soc Exp Biol Med 1994;206(3):268-72
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D, Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93(3):385-95
   PubMed Web of Science ®Google Scholar
• Decker T, Meinke A. Jaks, Stats and the immune system. Immunobiology 1997;198(1–3):99-111
   PubMed Web of Science ®Google Scholar
• Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors–an intimate relationship. Biochem Pharmacol 2006;72(11):1538-46
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Saharinen P, Pesu M, The Janus kinases (Jaks). Genome Biol 2004;5(12):253
   PubMed Web of Science ®Google Scholar
• Haque SJ, Sharma P. Interleukins and STAT signaling. Vitam Horm 2006;74:165-206
   PubMed Web of Science ®Google Scholar
• Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008;19(4):311-18
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Meraz MA, White JM, Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93(3):373-83
   PubMed Web of Science ®Google Scholar
• Neubauer H, Cumano A, Muller M, Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93(3):397-409
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakajima H, Saito Y, Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000;12(2):123-32
   PubMed Web of Science ®Google Scholar
• Shimoda K, Kato K, Aoki K, Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13(4):561-71
   PubMed Web of Science ®Google Scholar
• Thompson JE, Cubbon RM, Cummings RT, Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002;12(8):1219-23
   PubMed Web of Science ®Google Scholar
• Tasocitinib. Drugs R D 2010;10(4):271-84
   PubMedGoogle Scholar
• Flanagan ME, Blumenkopf TA, Brissette WH, Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53(24):8468-84
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186(7):4234-43
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Vaddi K, Liu P, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184(9):5298-307
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann RM, Cohen SB, Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):408
   Google Scholar
• Vanhoutte F, Galien R, Vets E, GLPG0634 shows selective inhibition of JAK1 and maintained JAK-STAT suppression in healthy volunteers [abstract]. Arthritis Rheum 2011;63(Suppl 10):2210
   Google Scholar
• van der Heijde D Tanaka Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):2592
   Google Scholar
• Burmester G-R, Blanco R, Charles-Schoeman C, Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):718
   Google Scholar
• Cohen S, Radominski SC, Asavatanabodee P, Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across phase 3 and long-term extension studies in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63(Suppl 10):409
   Google Scholar
• Williams W, Scherle P, Shi J, A randomized, placebo-controlled study of INCB018424, a selective Janus kinase 1 and 2 (Jak 1&2) inhibitor in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2008;60(Suppl 10):714
   Google Scholar
• Greenwald MW, Fidelus-Gort R, Levy R, A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract]. Arthritis Rheum 2010;62(Suppl 10):2172
   Google Scholar
• Fleischman R, Spencer-Green GT, Fan F, Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2011;63(Suppl 10):L3
   Google Scholar
• Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67(7):909-16
   PubMed Web of Science ®Google Scholar
• Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 2011;29(6):467-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006;33(8):1516-22
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Chang E, Yamashita S, Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15(10):1556-61
   PubMed Web of Science ®Google Scholar
• del Rincon I, Freeman GL, Haas RW, Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52(11):3413-23
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Yamasaki S, Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31(4):451-6
   PubMed Web of Science ®Google Scholar